4577 Daito Pharmaceutical Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4577

TSE Prime

Daito Pharmaceutical Co.,Ltd.

1,255

JPY

-5

(-0.40%)

Apr 30, 11:13 am JST

7.83

USD

Apr 29, 10:13 pm EDT

Result

PTS

outside of trading hours

1,255

Apr 30, 11:13 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2022	43,464	6,553	6,729	4,668	152.5	27.27	Jul 14, 2022	J-GAAP
May, 2023	45,101	5,207	5,169	3,600	113.8	27.27	Jul 14, 2023	J-GAAP
May, 2024	46,895	3,894	3,923	3,295	105.0	30	Jul 12, 2024	J-GAAP
May, 2025	50,643	2,619	2,705	1,908	62.7	35	Jul 11, 2025	J-GAAP
May, 2026 Guidance	51,000	3,300	3,500	2,500	86.7	40	Apr 10, 2026	J-GAAP
YoY	+0.7%	+26.0%	+29.4%	+31.0%	+38.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
May, 2021	Jul 10, 2020	47,500	4,950	5,000	3,400	20.91	J-GAAP
	Apr 14, 2021	48,900	5,900	6,000	4,000	20.91	J-GAAP
Results	Jul 14, 2021	48,714	5,908	6,067	4,246	20.91	J-GAAP
May, 2022	Jul 14, 2021	Available in future release
	Apr 14, 2022
Results	Jul 14, 2022
May, 2023	Jul 14, 2022
Results	Jul 14, 2023
May, 2024	Jul 14, 2023
	Jun 25, 2024
Results	Jul 12, 2024
May, 2025	Jul 12, 2024
	Apr 14, 2025
Results	Jul 11, 2025
May, 2026	Jul 11, 2025	52,500	3,000	3,000	2,300	40*	J-GAAP
	Apr 10, 2026	51,000	3,300	3,500	2,500	40*	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
May, 2005	14,172	－	Available in future release
May, 2006	15,542	+9.7
May, 2007	16,990	+9.3
May, 2008	20,756	+22.2
May, 2009	21,522	+3.7
May, 2010	22,678	+5.4
May, 2011	25,225	+11.2
May, 2012	27,151	+7.6
May, 2013	28,956	+6.6
May, 2014	31,196	+7.7
May, 2015	34,058	+9.2
May, 2016	36,370	+6.8
May, 2017	37,984	+4.4
May, 2018	39,875	+5.0
May, 2019	41,134	+3.2
May, 2020	44,991	+9.4
May, 2021	48,714	+8.3
May, 2022	43,464	-10.8
May, 2023	45,101	+3.8
May, 2024	46,895	+4.0
May, 2025	50,643	+8.0
May, 2026 Guidance	51,000	+0.7	3,300	+26.0	3,500	+29.4	86.7	+38.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
May, 2024	46,895	3,894	8.30	6.41	4.44	0.63	105.0
May, 2025	50,643	2,619	5.17	3.67	2.45	0.65	62.7
May, 2026 Guidance	51,000	3,300	6.47	4.78	3.33	0.68	86.7

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	50,643	6,553	6,729	4,668	152.5
Fiscal Year	May, 2025	May, 2022	May, 2022	May, 2022	May, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec - May, 2022	21,734	2,381	2,417	1,838	58.1	13.63	Jul 14, 2023	J-GAAP
Dec - May, 2023	22,785	1,605	1,609	1,743	55.5	15	Jul 12, 2024	J-GAAP
Dec - May, 2024	26,059	1,148	1,235	1,000	32.9	17.50	Jul 11, 2025	J-GAAP
Dec - May, 2025 Guidance	25,859	1,673	1,736	1,267	43.9	20	Apr 10, 2026	J-GAAP
YoY	-0.8%	+45.7%	+40.6%	+26.7%	+33.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
May, 2023	5,207	-1,411	4,155	-5,566	616	3,607	5.11	J-GAAP
May, 2024	3,894	-748	5,182	-5,930	-183	2,727	3.51	J-GAAP
May, 2025	2,619	-1,468	5,897	-7,365	1,002	2,207	2.83	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Feb, 2023	34,662	3,105	3,122	2,339	74.2	79.6	Apr 12, 2024	J-GAAP
Jun - Feb, 2024	36,609	1,869	2,033	1,217	39.9	75.2	Apr 14, 2025	J-GAAP
Jun - Feb, 2025	36,732	2,751	2,974	2,267	76.5	85.0	Apr 10, 2026	J-GAAP
YoY	+0.3%	+47.2%	+46.3%	+86.3%	+91.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Mar - May, 2024	12,233	789	801	956	30.5	6.4	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	12,678	849	983	618	20.2	6.7	Oct 11, 2024	J-GAAP
Sep - Nov, 2024	11,906	622	487	290	9.5	5.2	Jan 10, 2025	J-GAAP
Dec - Feb, 2024	12,025	398	563	309	10.1	3.3	Apr 14, 2025	J-GAAP
Mar - May, 2025	14,034	750	672	691	22.7	5.3	Jul 11, 2025	J-GAAP
Jun - Aug, 2025	13,011	998	1,052	696	23.2	7.7	Oct 10, 2025	J-GAAP
Sep - Nov, 2025	12,130	629	712	537	18.0	5.2	Jan 14, 2026	J-GAAP
Dec - Feb, 2025	11,591	1,124	1,210	1,034	34.9	9.7	Apr 10, 2026	J-GAAP
YoY	-3.6%	+182.4%	+114.9%	+234.6%	+245.0%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar - May, 2021	10,879	+2.4	Available in future release
Jun - Aug, 2021	11,746	-14.3
Sep - Nov, 2021	10,717	-13.1
Dec - Feb, 2021	11,120	-5.8
Mar - May, 2022	9,881	-9.2
Jun - Aug, 2022	12,041	+2.5
Sep - Nov, 2022	11,326	+5.7
Dec - Feb, 2022	11,203	+0.7
Mar - May, 2023	10,531	+6.6
Jun - Aug, 2023	12,178	+1.1
Sep - Nov, 2023	11,932	+5.4
Dec - Feb, 2023	10,552	-5.8
Mar - May, 2024	12,233	+16.2
Jun - Aug, 2024	12,678	+4.1
Sep - Nov, 2024	11,906	-0.2
Dec - Feb, 2024	12,025	+14.0
Mar - May, 2025	14,034	+14.7
Jun - Aug, 2025	13,011	+2.6
Sep - Nov, 2025	12,130	+1.9
Dec - Feb, 2025	11,591	-3.6	1,124	+182.4	1,210	+114.9	34.9	+245.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	14,034	2,360	2,419	1,825	60.5
Fiscal Year	May, 2025	Aug, 2021	Aug, 2021	Aug, 2021	Aug, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
May, 2023	3,206.50	71.8	70,552	50,672	35,006	0.10	Jul 14, 2023	J-GAAP
May, 2024	3,404.70	67.0	77,708	52,068	37,087	0.17	Jul 12, 2024	J-GAAP
May, 2025	3,468.52	66.7	78,004	52,003	37,179	0.23	Jul 11, 2025	J-GAAP
Jun - Feb, 2025	ー	69.7	74,963	52,261	37,702	0.19	Apr 10, 2026	J-GAAP

Daito Pharmaceutical Co.,Ltd.(4577) Financial Results